Nanomedicine for the cardiac myocyte: Where are we?

Lozano, Omar; Torres‐Quintanilla, Alejandro; García‐Rivas, Gerardo

doi:10.1016/j.jconrel.2017.12.018

Cited by 25 publications

(24 citation statements)

References 140 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, these events may have prompted the sustained opening of the Kir6.2 channels to reduce the heart rate, a survival mechanism described elsewhere during metabolic inhibition and ischemia [4,25,32]. Studies on the effects of cardiac contraction due to nanoparticle exposure are scarce [40]. In adult rat cardiomyocytes exposed during 24 h to the same nanoSiO 2 as this study, a reduction in contractility, assessed by reduced cell shortening, was reported.…”

Section: Discussionmentioning

confidence: 52%

“…Amorphous SiO 2 has been reported to elicit less toxicity in vitro or in vivo than its crystalline counterparts, and most nanotoxicity studies have been performed in amorphous nanoSiO 2 [44]. Specifically, in cardiomyocyte research, nanoSiO 2 has been reported only in relation to nanotoxicology rather than applications [40]. For NPs in general, particle size and particle number are the major drivers of a toxicological response.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Amorphous SiO2 nanoparticles promote cardiac dysfunction via the opening of the mitochondrial permeability transition pore in rat heart and human cardiomyocytes

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: Silica nanoparticles (nanoSiO 2) are promising systems that can deliver biologically active compounds to tissues such as the heart in a controllable manner. However, cardiac toxicity induced by nanoSiO 2 has been recently related to abnormal calcium handling and energetic failure in cardiomyocytes. Moreover, the precise mechanisms underlying this energetic debacle remain unclear. In order to elucidate these mechanisms, this article explores the ex vivo heart function and mitochondria after exposure to nanoSiO 2 .

show abstract

Section: Discussionmentioning

confidence: 52%

Section: Discussionmentioning

confidence: 99%

Amorphous SiO2 nanoparticles promote cardiac dysfunction via the opening of the mitochondrial permeability transition pore in rat heart and human cardiomyocytes

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…The search for better treatments for cardiac dysfunction continues nowadays, even when several key mechanisms of the disease have been identified [16]. This is the case for diseases associated with an overproduction of ROS, for example, after an I-R event [3].…”

Section: Discussionmentioning

confidence: 99%

Nanoencapsulated Quercetin Improves Cardioprotection during Hypoxia-Reoxygenation Injury through Preservation of Mitochondrial Function

Lozano

Lázaro‐Alfaro

Silva-Platas

et al. 2019

Oxidative Medicine and Cellular Longevity

Self Cite

View full text Add to dashboard Cite

The effective delivery of antioxidants to the cells is hindered by their high metabolization rate. In this work, quercetin was encapsulated in poly(lactic-co-glycolic) acid (PLGA) nanoparticles. They were characterized in terms of its physicochemical properties (particle size distribution, ζ-potential, encapsulation efficiency, quercetin release and biological interactions with cardiac cells regarding nanoparticle association, and internalization and protective capability against relevant challenges). A better delivery of quercetin was achieved when encapsulated versus free. When the cells were challenged with antimycin A, it resulted in lower mitochondrial O2- (4.65- vs. 5.69- fold) and H2O2 rate production (1.15- vs. 1.73- fold). Similarly, under hypoxia-reoxygenation injury, a better maintenance of cell viability was found (77 vs. 65%), as well as a reduction of thiol groups (~70 vs. 40%). Therefore, the delivery of encapsulated quercetin resulted in the preservation of mitochondrial function and ATP synthesis due to its improved oxidative stress suppression. The results point to the potential of this strategy for the treatment of oxidative stress-based cardiac diseases.

show abstract

“…These fatal diseases are always characterized by acute inflammatory response and elevated oxidative stress that need to be rapidly eliminated in clinical treatment [ 276 , 277 ]. Recently, there has been increasing interest in advanced drug delivery systems for the treatment of acute CVDs [ 46 , 49 , 66 , [278] , [279] , [280] , [281] ]. Among them, bioresponsive materials and systems show considerable advantages in site-specific delivery and responsive release of different therapeutic agents at diseased tissues [ 282 , 283 ].…”

Section: Treatment Of Inflammatory Diseases By Bioresponsive Drug Delmentioning

confidence: 99%

Bioresponsive drug delivery systems for the treatment of inflammatory diseases

Ding

et al. 2020

Journal of Controlled Release

103

View full text Add to dashboard Cite

Inflammation is intimately related to the pathogenesis of numerous acute and chronic diseases like cardiovascular disease, inflammatory bowel disease, rheumatoid arthritis, and neurodegenerative diseases. Therefore anti-inflammatory therapy is a very promising strategy for the prevention and treatment of these inflammatory diseases. To overcome the shortcomings of existing anti-inflammatory agents and their traditional formulations, such as nonspecific tissue distribution and uncontrolled drug release, bioresponsive drug delivery systems have received much attention in recent years. In this review, we first provide a brief introduction of the pathogenesis of inflammation, with an emphasis on representative inflammatory cells and mediators in inflammatory microenvironments that serve as pathological fundamentals for rational design of bioresponsive carriers. Then we discuss different materials and delivery systems responsive to inflammation-associated biochemical signals, such as pH, reactive oxygen species, and specific enzymes. Also, applications of various bioresponsive drug delivery systems in the treatment of typical acute and chronic inflammatory diseases are described. Finally, crucial challenges in the future development and clinical translation of bioresponsive anti-inflammatory drug delivery systems are highlighted.

show abstract

Nanomedicine for the cardiac myocyte: Where are we?

Cited by 25 publications

References 140 publications

Amorphous SiO2 nanoparticles promote cardiac dysfunction via the opening of the mitochondrial permeability transition pore in rat heart and human cardiomyocytes

Amorphous SiO2 nanoparticles promote cardiac dysfunction via the opening of the mitochondrial permeability transition pore in rat heart and human cardiomyocytes

Nanoencapsulated Quercetin Improves Cardioprotection during Hypoxia-Reoxygenation Injury through Preservation of Mitochondrial Function

Bioresponsive drug delivery systems for the treatment of inflammatory diseases

Contact Info

Product

Resources

About